An observational study in Papillary Thyroid Carcinoma, sponsored by The Affiliated Hospital of Inner Mongolia Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-20.
Sponsored by The Affiliated Hospital of Inner Mongolia Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Thyroid Cancer, Papillary with a site in China — 24 open to participants now, 25 under way, 1 of them phase 3. Thyroid Cancer, Papillary · China.
Among the 40 studies in Thyroid Cancer, Papillary with a site in China, this one is the 19th largest by planned enrollment of the 19 observational ones that give a count, is one of 3 that started in 2016, is one of 19 observational ones, reaches primary completion later than 0 of the 24 other live ones, and was the 5th registered.
187 studies on the registry are indexed under Thyroid Cancer, Papillary; 50 are open to participants now.
Browse Thyroid Cancer, Papillary studies →24 of the 40 studies in Thyroid Cancer, Papillary with a site in China are open now. Recruiting first, the newest first:
Ming-an Yu · Sites in China
Ages 16–60
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Second Affiliated Hospital of Xi'an Jiaotong University · Sites in China
Ages 16–80
Shanghai 6th People's Hospital · Sites in China
Chinese PLA General Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 31 Thyroid Cancer, Papillary studies recruiting now, 18 (58%) set no upper age limit and 8 (26%) stop at 75 or younger; 13 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 1 · Phase 4 2
First in 2015; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 32 is below the median of 200 across 67 observational studies indexed under Thyroid Cancer, Papillary.
Median enrollment 170 across the 21 interventional studies, 541 across the 19 observational. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 40 have an industry lead sponsor. The 10 most frequent:
The Affiliated Hospital of Inner Mongolia Medical University is the lead sponsor of 9 studies on the registry; 8 are open to participants now.
The Affiliated Hospital of Inner Mongolia Medical University has 1 study filed under Thyroid Cancer, Papillary — fewer than ten, so there is no comparison to draw.
5 of the studies in Thyroid Cancer, Papillary with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07357571Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityPreoperative Prediction of Lymph Node Metastasis in T1N0M0 Papillary Thyroid Carcinoma by Using Contrast-enhanced Ultrasound | 2026-12-31 |
| NCT06316895Chinese PLA General HospitalThe Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma | 2027-04-01 |
| NCT06804863West China HospitalRegret Emotion After Thyroidectomy in Low-Risk Papillary Thyroid Cancer | 2027-05-01 |
| NCT06610604Ming-an YuHealth-Related Quality of Life and Emotions in Patients with Thyroid Nodules | 2027-06 |
| NCT02650401Hoffmann-La RocheStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 40 studies in Thyroid Cancer, Papillary with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Thyroid carcinoma is the common endocrine system malignant neoplasm. At present it has become the malignant neoplasm of fastest growing incidence rate. More than 85% thyroid carcinoma is papillary thyroid carcinoma. Cervical lymph node metastasis is common in papillary thyroid carcinoma patients. This study aim to reveal protein expression differences between papillary thyroid carcinoma with cervical lymph node metastasis and without cervical lymph node metastasis.
Patients aged 18-65 years; newly diagnosed papillary thyroid carcinoma with cervical lymph node metastasis and without cervical lymph node metastasis and undergone thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
papillary thyroid carcinoma patients with cervical lymph node metastasis
papillary thyroid carcinoma patients without cervical lymph node metastasis
benign disease
histologically normal
differences in protein expression
Time frame: 6 months
Plan to share: Undecided
The record gives a start of Jun 2016, a primary completion of Dec 2023 and a completion of Jun 2024. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Affiliated Hospital of Inner Mongolia Medical University